Zobrazeno 1 - 10
of 49
pro vyhledávání: ''
Autor:
Matteo Bassetti, Elda Righi
Publikováno v:
Expert Opinion on Drug Safety. 15:467-481
Methicillin-resistant Staphylococcus aureus (MRSA) is a frequent cause of severe nosocomial and community-acquired infections. Various adverse effects have been associated with compounds that are commonly used in the treatment of MRSA.Prolonged use o
Publikováno v:
Expert Opinion on Therapeutic Patents. 26:281-289
Diarylpyrimidine and diaryltriazine derivatives, two representative structurally related classes of HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) with robust potencies against wild-type and several mutant strains of HIV-1, have attra
Publikováno v:
Expert Opinion on Drug Safety. 14:1649-1652
Treatment of chronic hepatitis C virus (HCV) therapy has rapidly changed since the approval of IFN in the 1990s. Early treatment brought about significant and therapy limiting adverse drug events (ADEs) such as anemia. Since the direct-acting antivir
Autor:
Helen W. Boucher, Sheena Ramdeen
Publikováno v:
Expert Opinion on Pharmacotherapy. 16:2073-2081
Acute bacterial skin and skin structure infections (ABSSSI) have increased in incidence and severity. The involvement of resistant organisms, particularly methicillin-resistant Staphylococcus aureus, presents additional challenges. The lipoglycopepti
Autor:
Antonio Riccardo Buonomo, Guglielmo Borgia, Ivan Gentile, Emanuela Zappulo, Alberto Enrico Maraolo
Publikováno v:
Expert Opinion on Investigational Drugs. 24:1111-1121
About 185,000,000 people worldwide are chronically infected with hepatitis C virus (HCV). Currently, the most successful HCV infection antiviral therapies reduce the chance of progression towards the advanced phases of the hepatopathy (liver cirrhosi
Publikováno v:
Expert Opinion on Drug Metabolism & Toxicology. 11:1157-1165
Introduction: Telaprevir is one of the first direct-acting antiviral drugs approved for the treatment of the hepatitis C virus (HCV) genotype 1. Following its approval in 2011, new data regarding the pharmacokinetics and pharmacodynamics were reporte
Publikováno v:
Expert Opinion on Pharmacotherapy. 16:617-624
INTRODUCTION: Treatment of hepatitis C virus (HCV) infection with direct-acting antivirals (DAAs) has revolutionized the care of infected patients. Among these novel compounds are non-nucleoside analogs, which bind viral RNA- dependent RNA polymerase
Autor:
Guido Stirnimann
Publikováno v:
Expert Opinion on Pharmacotherapy. 15:2609-2622
Chronic hepatitis C infection is a global disease with 160 million people infected worldwide. Until recently, therapy was characterized by long duration, suboptimal success rates and significant adverse drug reactions. The development of direct-actin
Autor:
Evangelista Sagnelli, Salvatore Martini, Mariantonietta Pisaturo, Pietro Filippini, Nicola Coppola, Caterina Sagnelli
Publikováno v:
Expert Opinion on Pharmacotherapy. 15:1337-1349
Introduction: Patients with chronic hepatitis B virus (HBV)/hepatitis C virus (HCV) coinfection are at a high risk of developing liver cirrhosis and hepatocellular carcinoma, and consequently, warrant effective treatment.Areas covered: Effective trea
Autor:
Emanuela Zappulo, Giuseppe Castaldo, Antonio Riccardo Buonomo, Federico Borgia, Ivan Gentile, Guglielmo Borgia
Publikováno v:
Expert Opinion on Investigational Drugs. 23:719-728
Approximately 170 million people worldwide are chronic carriers of the hepatitis C virus (HCV). Twenty-five percent of them develop liver cirrhosis and hepatocellular carcinoma during their life. Successful antiviral treatment dramatically reduces th